Discussion Group Announcement
Our monthly Discussion Groups are hosted by a panel of leading industry experts who explore some of the key issues facing biologics research and development today. The interactive sessions provide a focused networking opportunity for a handful of like-minded experts in an online format.
- Most Anticipated Presentations: Vaccines Europe
- US Doubles its Supply of Monkeypox Vaccines
- Discussion Group Report: Oral Delivery of Peptides
Bringing together an exclusive panel of key opinion leaders for an hour of specialist discussion, each session addresses the critical growth factors, challenges, and future opportunities for the expansive biologics field and market.
For the next round of Discussion Groups, we will be exploring cutting-edge vaccine technologies and applications, as well as developing the next generation of biotherapeutics. With an array of hand-picked panel experts lined-up to lead stimulating and thought-provoking debates, these exclusive sessions are not-to-be-missed!
-
1.) Advanced Vaccine Platforms & Technologies
Taking place Friday 9th September 2022 | 15:00 BST (09:00 EST)
Discussion Topics:
- Vaccine platform technologies
- Development of modern vaccine technologies (mRNA, viral vectors, DNA and rapid response platforms)
- Industry opportunities and challenges
Discussion Leaders:
- Wieslaw Swietnicki, Head Of Research And Development at ?ukasiewicz Research Network – Institute of Industrial Organic Chemistry
- Slobodanka Dina Manceva, Senior Scientist at Teva Pharma
Oxford Global's Discussion Groups
2.) Exploring & Developing Various Biotherapeutics Modalities
Taking place Tuesday 18 October 2022 | 15:00 BST (09:00 EST)
Discussion Topics:
- Accelerating the development of next-generation therapeutics
- Overcoming challenges in analytical method development
Discussion Leaders:
- Peter D. Westenskow, Senior Principal Scientist and Section Head at Roche Pharma Research & Early Development
- Slobodanka Dina Manceva, Associate Director at Teva Pharma
- Smita Raghava, Associate Principal Scientist at Merck
- Jonathan Davis, Vice President of Innovation and Strategy at Invenra
-ion Groups
3.) Universal Vaccines & Vaccine Therapeutics
Taking place Thursday 3 November 2022 | 15:00 GMT (11:00 EDT)
Discussion Topics:
- Existing and Approved Immunotherapies
- Broadening the Horizons for Immunotherapy
- Understanding Mechanisms of Action
Discussion Leaders:
- Mark Doherty, Senior Medical Manager at GSK
- Slobodanka Dina Manceva, Senior Scientist at Teva Pharma
-
Attendance to our Discussion Groups is available to members of our Biologics Member Community. For more information about Membership, please click here.
Join Oxford Global‘s 2023 Biologics UK: In-Person event today. Happening in March, this 3-day conference brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data, and exciting industry outlooks.
Get your bi-weekly dose of industry news here and keep up to date with the latest 'Industry Spotlight' posts. For other Biologics content, please visit the Biologics Content Portal.
